HIF-1alpha and cancer therapy.
Most solid tumors develop regions of hypoxia as they grow and outstrip their blood supply. In order to survive in the stressful hypoxic environment, tumor cells have developed a coordinated set of responses orchestrating their adaptation to hypoxia. The outcomes of the cellular responses to hypoxia are aggressive disease, resistance to therapy, and decreased patient survival. A critical mediator of the hypoxic response is the transcription factor hypoxia-inducible factor 1 (HIF-1) that upregulates expression of proteins that promote angiogenesis, anaerobic metabolism, and many other survival pathways. Regulation of HIF-1alpha, a component of the HIF-1 heterodimer, occurs at multiple levels including translation, degradation, and transcriptional activation, and serves as a testimony to the central role of HIF-1. Studies demonstrating the importance of HIF-1alpha expression for tumor survival have made HIF-1alpha an attractive target for cancer therapy. The growing l.ist of pharmacological inhibitors of HIF-1 and their varied targets mirrors the complex molecular mechanisms controlling HIF-1. In this chapter, we summarize recent findings regarding the regulation of HIF-1alpha and the progress made in identifying new therapeutic agents that inhibit HIF-1alpha.
Koh
Mei Yee
MY
Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Spivak-Kroizman
Taly R
TR
Powis
Garth
G
D000818:Animals; D015687:Cell Hypoxia; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000037:antagonists & inhibitors* / Q000502:physiology*; D007191:Indazoles / Q000627:therapeutic use; D009150:Mustard Compounds / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000209:etiology; D010666:Phenylpropionates / Q000627:therapeutic use; D016271:Proto-Oncogene Proteins c-myc / Q000502:physiology; D016159:Tumor Suppressor Protein p53 / Q000502:physiology
C492908:2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; D056572:Histone Deacetylase Inhibitors; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007191:Indazoles; D009150:Mustard Compounds; D010666:Phenylpropionates; D016271:Proto-Oncogene Proteins c-myc; D016159:Tumor Suppressor Protein p53; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole